for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Harbin Pharmaceutical Group Co., Ltd.

600664.SS

Latest Trade

3.18CNY

Change

0.02(+0.63%)

Volume

11,920,055

Today's Range

3.15

 - 

3.19

52 Week Range

2.38

 - 

3.68

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.16
Open
3.16
Volume
11,920,055
3M AVG Volume
437.61
Today's High
3.19
Today's Low
3.15
52 Week High
3.68
52 Week Low
2.38
Shares Out (MIL)
2,518.38
Market Cap (MIL)
7,958.07
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2021 Harbin Pharmaceutical Group Co Ltd Earnings Release

Latest Developments

More

Harbin Pharma Returns To 6-Month Net Profit

Harbin Pharmaceutical Expects To Return To Net Profit In H1

Harbin Pharmaceutical Swings To Net Loss Of 1.1 Bln Yuan In 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Company’s main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.

Industry

Biotechnology & Drugs

Contact Info

No. 7 Qunli Avenue, Daoli District

HAERBIN, HNG

150070

China

+86.451.51870077

http://www.hayao.com

Executive Leadership

Zhenping Zhang

Chairman of the Board

Bo Liu

Chief Accounting Officer, Director

Haiying Xu

General Manager

Zhijun Wu

Deputy General Manager, Director

Bangmin Liu

Deputy General Manager

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
0.62
Price To Book (MRQ)
2.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
74.49
LT Debt To Equity (MRQ)
2.78
Return on Investment (TTM)
-3.88
Return on Equity (TTM)
-1.49

Latest News

Latest News

U.S. senator asks for CFIUS review of GNC purchase by Chinese company

U.S. Senator Marco Rubio, a Republican and a China hawk, asked for a national security review of plans by General Nutrition Centers <GNC.N>, or GNC, to sell itself to Harbin Pharmaceutical Group Co Ltd.

US senator asks for CFIUS review of GNC purchase by Chinese company

U.S. Senator Marco Rubio, a Republican and a China hawk, asked for a national security review of plans by General Nutrition Centers, or GNC, to sell itself to Harbin Pharmaceutical Group Co Ltd.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up